Source: Emergia.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Emergia (EMER) has announced a conversion of its convertible debentures
  • A debenture holder exercised the conversion, initially issued on October 29, 2021, for a total amount of $425,000, at a price of $0.85 per unit, for a total of 500,000 units
  • In addition, the corporation executed an agreement where it converted $296,000 in debt into shares issued at $0.70 per share, representing 424,000 shares
  • Emergia operates mainly in Canada in the development, acquisition and management of multi-purpose real estate
  • Emergia (EMER) closed down by 2.86 per cent trading at $0.68 per share

Emergia (EMER) has announced a conversion of its convertible debentures.

A debenture holder exercised the conversion, initially issued on October 29, 2021, for a total amount of $425,000, at a price of $0.85 per unit, for a total of 500,000 units.

The debentures were bearing interest at 8 per cent annually, accruing in arrears, payable semi-annually in cash or in Class A common shares.

Each unit is made up of one share and two warrants.

Each warrant entitles the holder to purchase one share at a price of $1.25 until October 31, 2023, while the other warrant entitles the holder to purchase one share at a price of $1.50 until October 31, 2024.

In addition, the corporation executed an agreement where it converted $296,000 in debt into shares issued at $0.70 per share, representing 424,000 shares.

“The fact that investors chose to be paid in Emergia shares, driven by the discount on the stock price in the market compared to its net asset value, which was at $1.68 in the corporation’s Q3-2022 financial statements, show, again, the trust in Emergia’s business model,” said Henri Petit, President and CEO of Emergia.

Emergia operates mainly in Canada in the development, acquisition and management of multi-purpose real estate.

Emergia (EMER) closed down by 2.86 per cent trading at $0.68 per share.


More From The Market Herald

" Innocan Pharma (CSE:INNO) reports successful efficacy test for vaginal derma product

Innocan Pharma (INNO) has announced successful results from a controlled efficacy test of its vaginal derma product.

" @ the Bell: TSX bounces back again

Euro banking drama had a ripple effect felt on Bay Street Friday but Canada’s main stock index dodged another close in the red.
RBC

" Survey shows fraud risk a rising concern for Canadians

Latest survey by Royal Bank of Canada shows Canadians are concerned about spotting scams and that fraud risk will get worse if a recession

" A.I.S. Resources (TSXV:AIS) updates on its Argentina properties

A.I.S. Resources has provided an update to its Pocitos properties in the Salta, Argentina region.